Evaxion Biotech AS (EVAX) - Total Assets
Based on the latest financial reports, Evaxion Biotech AS (EVAX) holds total assets worth $28.41 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Evaxion Biotech AS service its debt to assess how comfortably operating cash covers total debt obligations.
Evaxion Biotech AS - Total Assets Trend (2017–2025)
This chart illustrates how Evaxion Biotech AS's total assets have evolved over time, based on quarterly financial data. See net assets of Evaxion Biotech AS for net asset value and shareholders' equity analysis.
Evaxion Biotech AS - Asset Composition Analysis
Current Asset Composition (December 2025)
Evaxion Biotech AS's total assets of $28.41 Million consist of 87.7% current assets and 12.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.8% |
| Accounts Receivable | $1.05 Million | 3.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Evaxion Biotech AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EVAX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evaxion Biotech AS's current assets represent 87.7% of total assets in 2025, a decrease from 92.9% in 2017.
- Cash Position: Cash and equivalents constituted 81.8% of total assets in 2025, up from 15.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 3.7% of total assets.
Evaxion Biotech AS Competitors by Total Assets
Key competitors of Evaxion Biotech AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Evaxion Biotech AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.85 | 2.01 | 1.18 |
| Quick Ratio | 5.85 | 2.01 | 2.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $20.64 Million | $4.40 Million | $907.00K |
Evaxion Biotech AS - Advanced Valuation Insights
This section examines the relationship between Evaxion Biotech AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.14 |
| Latest Market Cap to Assets Ratio | 0.83 |
| Asset Growth Rate (YoY) | 127.5% |
| Total Assets | $28.41 Million |
| Market Capitalization | $23.52 Million USD |
Valuation Analysis
Near Book Valuation: The market values Evaxion Biotech AS's assets close to their book value (0.83x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Evaxion Biotech AS's assets grew by 127.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Evaxion Biotech AS (2017–2025)
The table below shows the annual total assets of Evaxion Biotech AS from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $28.41 Million | +127.53% |
| 2024-12-31 | $12.48 Million | -3.13% |
| 2023-12-31 | $12.89 Million | -41.48% |
| 2022-12-31 | $22.02 Million | -45.16% |
| 2021-12-31 | $40.16 Million | +235.67% |
| 2020-12-31 | $11.96 Million | +7.95% |
| 2019-12-31 | $11.08 Million | +30.20% |
| 2018-12-31 | $8.51 Million | +188.67% |
| 2017-12-31 | $2.95 Million | -- |
About Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid le… Read more